Health Condition 1: N970- Female infertility associated withanovulation Health Condition 2: E282- Polycystic ovarian syndrome
Conditions
Interventions
None listed
Sponsors
Banaras Hindu University
Institute of Eminence Grant
Eligibility
Inclusion criteria
Inclusion criteria: Patients of female infertility who satisfied the Rotterdam criterion (2/3 of the features) for PCOS 1-Oligo/amenorrhea: Absence of menstruation for 45 days or more and/or less than eight menses per year. 2-Clinical hyperandrogenism, Modified Ferriman and Gallway (mFG) score of 6 or higher. Biochemical hyperandrogenism, serum LH and FSH ratio more than 2:1 3-Poly cystic ovaries: Presence of >10 cysts, 2-8 mm in diameter, usually combined with increased ovarian volume of >10 cm3, and an echo-dense stroma in pelvic ultrasound scan.
Exclusion criteria
Exclusion criteria: 1-Patients who use of oral contraceptives/hormone treatment/insulin-sensitizing agents within previous six weeks. 2-Patients who have addiction of alcohol,smoking and any prior experience of yoga 3-Patients who have Hyperprolactinemia, thyroid abnormalities and non-classic adrenal hyperplasia, and those who did not consent for the study. 4-Patients who have Primary ammenorheoa, Premature ovarian failure, absent ovary and uterus. 5-The patients suffering from diabetes mellitus, hypertension, thyroid disorders, hyper prolactinemia, congenital adrenal hyperplasia, other gynaecological disorders, and renal failure 6-Patients with evidence of malignancy 7-Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro-Endocrinal disorders, etc.) 8-Patients who have a past history of Atrial Fibrillation, Coronary Artery Disease (CAD), Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 9-Symptomatic patient with clinical evidence of Heart failure. 10-Patients on prolonged ( > 6 weeks) medication with corticosteoids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. 11-Patients who have completed participation in any other clinical trial during the past six (06) months. 12-Any other condition which the Principal Investigator thinks may jeopardize the study Study Duration : 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| to assess the change in ovarian morphology in terms of ovulation, rate and judged by transvaginal USG of ovaries on 9th to 11th day of cycleTimepoint: 12 weeks and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. To asses changes in anthropometric measurements (body weight, body mass index [BMI], chest circumference, waist circumference, hip circumference, mid-arm circumference, and waistâ??hip ratio) at the end of 12 weeks. 2. To Hospital Anxiety and Depression Scale [HADS] at end of every 12 weeks. 3. To of menstrual frequency at the end of every 4 weeks. Timepoint: 6 months | — |
Countries
India
Contacts
Public ContactDr Mamta Tiwari
Banaras Hindu University
Outcome results
None listed